Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI)is developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases, e.g. Amyotrophic Lateral Sclerosis (ALS a.k.a. Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD). NurOwn is the company’s own, first-of-its-kind technology that induces autologous bone marrow-derived Mesenchymal Stem Cells (MSCs) to secrete Neurotrophic Factors (NTF). These “MSC-NTF” cells can then be transplanted back into the patient at or near the site of damage, in the spine and/or muscles, for therapeutic purposes. For more information, visit the company’s website at www.brainstorm-cell.com.